CTNM - CIK 0001855175
The table below shows Contineum Therapeutics, Inc.'s cash flow statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating cash flow | -$55.31M | -$32.84M | $19.35M |
| Capital expenditure | $231.00K | $514.00K | $414.00K |
| Investing cash flow | -$3.71M | -$69.74M | -$65.57M |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $112.69M | $109.00M | $56.18M |
Contineum Therapeutics, Inc. reported operating cash flow of -$55.31M for fiscal year 2025. That is down 68.4% from -$32.84M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.